As European markets experience a wave of optimism amidst hopes for a shorter conflict in the Middle East, the pan-European STOXX Europe 600 Index has seen a notable rise of 3.92%. In this context, growth companies with high insider ownership can be particularly appealing as they often reflect strong internal confidence and potential resilience against market volatility.
Name
Insider Ownership
Earnings Growth
MedinCell (ENXTPA:MEDCL)
11.5%
117.6%
KebNi (OM:KEBNI B)
35%
80.1%
Induct (OB:INDCT)
10.5%
98.6%
Elliptic Laboratories (OB:ELABS)
21.6%
124.9%
Devyser Diagnostics (OM:DVYSR)
29.6%
68.3%
CTT Systems (OM:CTT)
17.4%
42.7%
Clavister Holding AB (publ.) (OM:CLAV)
18%
116.2%
Circus (XTRA:CA1)
21.9%
88.1%
Bonesupport Holding (OM:BONEX)
10.2%
34%
Bergen Carbon Solutions (OB:BCS)
10.2%
55.5%
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NTG Nordic Transport Group A/S, along with its subsidiaries, offers asset-light freight forwarding services across road, rail, air, and ocean in Denmark, Germany, the United States, Sweden, Finland and internationally; it has a market cap of DKK3.70 billion.
Operations: The company’s revenue is primarily generated from its Road & Logistics segment, which accounts for DKK8.92 billion, and the Air & Ocean segment, contributing DKK2.50 billion.
Insider Ownership: 14.5%
NTG Nordic Transport Group, a growth-oriented company with significant insider ownership, is poised for substantial earnings growth at 20.4% per year, outpacing the Danish market. Despite a forecasted slower revenue increase of 3.7%, strategic leadership changes like appointing Carsten Trolle as CEO of Air & Ocean aim to enhance global expansion efforts. Recent share buybacks and capital authorizations indicate proactive financial management, although profit margins have declined from last year.
CPSE:NTG Ownership Breakdown as at Apr 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer treatment globally, with a market cap of approximately SEK6.66 billion.
Operations: The company generates revenue from its healthcare software segment, amounting to SEK1.34 billion.
